| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 272,551 | 164,677 | 211,007 | NaN |
| Cost of product, collaboration and license sales | 19,679 | 186 | 12,441 | NaN |
| Program spend | 37,544 | 57,903 | 45,940 | NaN |
| Employee costs | 76,121 | 85,821 | 64,470 | NaN |
| Manufacturing costs | 9,085 | 21,806 | 11,047 | NaN |
| Administrative costs | 16,688 | 18,881 | 18,614 | NaN |
| Occupancy costs | 8,354 | 7,883 | 7,853 | NaN |
| Total other segment items | 107,889 | 107,162 | 34,746 | NaN |
| Net (loss) income | -2,809 | -134,965 | 15,896 | 801,713 |
| Depreciation and amortization | 15,413 | 12,902 | 11,109 | 14,804 |
| Non-cash operating lease expense | 1,761 | 1,832 | 2,001 | 3,634 |
| Non-cash royalty revenue related to sale of future royalties | 46,835 | 79,408 | 64,061 | 85,099 |
| Non-cash interest expense on liability related to sale of future royalties | 65,699 | 65,853 | 49,976 | 99,329 |
| Tangible asset impairment | NaN | NaN | NaN | 100 |
| Change in valuation of contingent consideration | NaN | 0 | 0 | -800 |
| Loss on sale of fixed assets | NaN | NaN | NaN | -77 |
| Tangible asset impairment | NaN | 500 | 419 | 99 |
| Loss on sale of fixed assets | NaN | 0 | -30 | -100 |
| Payments on contingent consideration | NaN | 0 | 0 | -4,684 |
| Gain on lease modification | NaN | 10,775 | NaN | NaN |
| Unrealized (gain) loss on clearpoint equity investments | NaN | 0 | 8,812 | -3,078 |
| Realized loss on sale of clearpoint equity investment | NaN | -7,081 | NaN | NaN |
| Tangible asset impairment and losses on transactions, net | -927 | NaN | NaN | NaN |
| Unrealized gain on marketable securities - equity investments | 1,214 | 800 | 1,622 | 1,538 |
| Disposal of asset | NaN | 0 | -163 | NaN |
| Deferred income taxes | -10 | 1 | -4 | NaN |
| Amortization of discounts on investments, net | 4,114 | 5,050 | 6,103 | 6,869 |
| Amortization of debt issuance costs | 305 | 313 | 305 | 601 |
| Share-based compensation expense | 23,421 | 18,518 | 19,426 | 36,603 |
| Unrealized foreign currency transaction losses, net | 887 | 1,388 | 171 | -4,939 |
| Inventory, net | -2,643 | 26,779 | 18,526 | 8,591 |
| Prepaid expenses and other current assets | -1,180 | 22,942 | 1,679 | 12,197 |
| Trade and royalty receivables, net | 40,390 | -22,214 | 6,474 | 25,891 |
| Deposits and other assets | 1,588 | -1,137 | -2,328 | 827 |
| Accounts payable and accrued expenses | -68,713 | 108,082 | -43,205 | 6,864 |
| Other liabilities | -2,309 | 9,101 | -9,177 | -17,320 |
| Deferred revenue | -1,522 | 300 | -8,143 | 3,845 |
| Net cash (used in) provided by operating activities | -59,042 | -34,273 | -66,301 | 811,770 |
| Purchases of fixed assets | 1,197 | 2,374 | 3,445 | 3,041 |
| Proceeds from sale of fixed assets | NaN | 0 | 0 | 70 |
| Purchases of marketable securities- available for sale | 454,670 | 312,263 | 204,103 | 847,164 |
| Purchases of marketable securities- equity investments | 23,957 | 7,091 | 29,508 | 17,029 |
| Sale of marketable securities- available for sale | 376,359 | 359,545 | 177,200 | 247,151 |
| Sale of marketable securities- equity investments | 9,885 | 18,696 | 22,983 | 17,129 |
| Sale of clearpoint equity investments | NaN | 12,412 | NaN | NaN |
| Acquisition of product rights and licenses | 156 | 34,917 | 252,750 | 3,485 |
| Net cash used in investing activities | -93,736 | 34,008 | -289,623 | -606,369 |
| Proceeds from employee stock purchase plan | NaN | 3,117 | 0 | 2,827 |
| Proceeds from exercise of options | 6,403 | 59,387 | 16,830 | 16,885 |
| Cash consideration received from a&r royalty purchase agreement | NaN | 240,000 | NaN | NaN |
| Payments on contingent consideration obligation | NaN | 0 | 0 | 6,341 |
| Payment of finance lease principal | NaN | 0 | 1,611 | NaN |
| Net cash provided by financing activities | 6,403 | 302,504 | 15,219 | 13,371 |
| Effect of exchange rate changes on cash | -1,524 | 9,795 | -6,064 | 18,981 |
| Net (decrease) increase in cash and cash equivalents | -147,899 | 312,034 | -346,769 | 237,753 |
| Cash and cash equivalents, and restricted cash beginning of period | 686,300 | NaN | 795,316 | NaN |
| Cash and cash equivalents, and restricted cash end of period | 850,435 | NaN | 686,300 | NaN |
PTC THERAPEUTICS, INC. (PTCT)
PTC THERAPEUTICS, INC. (PTCT)